Keyword: Dupixent

The new eczema data came a month ahead of an expected FDA decision on the drug's fate in asthma.

Only days after the FDA turned away Regeneron's Eylea for a label expansion, the drugmaker has secured the approval it sought.

What does severe eczema feel like? Sanofi and Regeneron's first Dupixent ads feature images—tiny crawling insects, for one—to illustrate just that.

As much as Sanofi has struggled with diabetes the past few years, it could typically count on vaccines and Genzyme—but not this quarter.

Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.

Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.

Formulary shutouts were already hurting Sanofi's diabetes numbers. But price cuts and Medicare compounded the pain in the first quarter of 2017.

The cost-effectiveness gatekeeper figures Dupixent works—and offers an option for patients who really need one—but isn't sure it's worth the price.